VRTX : Summary for Vertex Pharmaceuticals Incorpor - Yahoo Finance

U.S. Markets closed

Vertex Pharmaceuticals Incorporated (VRTX)


NasdaqGS - NasdaqGS Delayed Price. Currency in USD
Add to watchlist
108.01+18.34 (+20.45%)
At close: 4:00PM EDT

108.55 0.54 (0.50%)
After hours: 7:05PM EDT

People also watch
ALXNREGNBMRNINCYBIIB
Interactive chart
  • 1d
  • 5d
  • 1m
  • 6m
  • YTD
  • 1y
  • 2y
  • 5y
  • 10y
  • Max
1d
Previous Close89.67
Open106.30
Bid108.10 x 100
Ask108.55 x 200
Day's Range106.03 - 111.88
52 Week Range71.46 - 111.88
Volume13,681,019
Avg. Volume1,621,727
Market Cap26.83B
Beta2.08
PE Ratio (TTM)-234.80
EPS (TTM)N/A
Earnings DateN/A
Dividend & YieldN/A (N/A)
Ex-Dividend DateN/A
1y Target EstN/A
Trade prices are not sourced from all markets
  • Barrons.com2 hours ago

    The Hot Stock: Vertex Pharmaceuticals Soars 20%

    Vertex Pharmaceuticals gained 20% to $108.01 today, while the S&P 500 ticked up 0.1% to 2,361.13. Morgan Stanley's Matthew Harrison and team write that the data on Vertex's cystic fibrosis treatment was "as good as we could have hoped." They explain: [Last night's] data represent the best case scenario and we see VRTX quickly moving higher as it becomes a key stock to own for the 2H17 triple combination optionality. Vertex Pharmaceuticals' market capitalization rose to $26.8 billion today from $22.3 billion yesterday.

  • Reuters3 hours ago

    US STOCKS-Energy, consumer shares lift S&P 500 to slight gain

    The benchmark S&P 500 eked out a gain on Wednesday as strength in the energy and consumer sectors offset declines in financial shares and investors began looking ahead to first-quarter earnings season. The Dow Jones Industrial Average ended slightly lower, falling for the ninth session out of the past 10, while the Nasdaq rose for a fourth straight day. Investors have been assessing what the Republicans' failure to pass a healthcare bill means for tax reform and the rest of President Donald Trump's agenda, hopes for which have helped drive stocks to record highs.

  • Vertex Rockets To 14-Month High On Cystic Fibrosis Drug Results
    Investor's Business Daily3 hours ago

    Vertex Rockets To 14-Month High On Cystic Fibrosis Drug Results

    Vertex Pharmaceuticals stock rocketed Wednesday after the company unveiled strong cystic fibrosis drug data.